For more than 30 years, companies in the U.S. have been able to patent human genes, giving them exclusive rights to produce drugs, diagnostic tests or other tools based on those genes. But now the U.S. Supreme Court is revisiting this controversial issue. The high court heard arguments Monday in a case that has implications for medicine, agriculture, clean energy and beyond.   Myriad Genetics was the first company to identify two genes that, when defective, greatly increase a woman’s … [Read More]

—–
Source: VOA News: War and Conflict